Cancer immunotherapy-targeted glypican-3 or neoantigens

Yasuhiro Shimizu, Toshihiro Suzuki, Toshiaki Yoshikawa, Nobuhiro Tsuchiya, Yu Sawada, Itaru Endo, Tetsuya Nakatsura

Research output: Contribution to journalReview articlepeer-review

35 Citations (Scopus)


Immune checkpoint inhibitors have ushered in a new era in cancer therapy, although other therapies or combinations thereof are still needed for many patients for whom these drugs are ineffective. In this light, we have identified glypican-3 an HLA-24, HLA-A2 restriction peptide with extreme cancer specificity. In this paper, we summarize results from a number of related clinical trials showing that glypican-3 peptide vaccines induce specific CTLs in most patients (UMIN Clinical Trials Registry: UMIN000001395, UMIN000005093, UMIN000002614, UMN000003696, and UMIN000006357). We also describe the current state of personalized cancer immunotherapy based on neoantigens, and assess, based on our own research and experience, the potential of such therapy to elicit cancer regression. Finally, we discuss the future direction of cancer immunotherapy.

Original languageEnglish
Pages (from-to)531-541
Number of pages11
JournalCancer science
Issue number3
Publication statusPublished - 2018 Mar
Externally publishedYes


  • cancer vaccine
  • CAR-transduced T-cell therapy
  • glypican-3
  • neoantigen
  • TCR-transduced T-cell therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cancer immunotherapy-targeted glypican-3 or neoantigens'. Together they form a unique fingerprint.

Cite this